Strategy

Oct 01, 2006
Pharmaceutical Executive
The problem isn't that there's conflict between safety and efficacy or between getting a useful medicine to market and protecting the public from a dangerous one. The problem is that the conflict isn't well structured. That needs to change.
Oct 01, 2006
Pharmaceutical Executive
Almost $60 billion of the drug industry's global sales comes from just 10 drugs. In fact, these so-called "mega-brands" have sales so high that they are bigger than many Fortune 500 companies. So why aren't they being managed that way?
Sep 01, 2006
Pharmaceutical Executive
These "guns for hire" bring the science and marketing savvy that clients need, often with in-depth category experience, but without the commitment and cost associated with hiring a full-time employee.
Sep 01, 2006
Pharmaceutical Executive
Advice for new leaders: Forget the irrelevant meetings, the 300 e-mails, and the 50 voicemails.
Sep 01, 2006
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Just because outside contractors and vendors are experts does not mean everything will happen exactly the way you want it to. There's a lot of oversight.
Apr 01, 2006
Pharmaceutical Executive
By Pharmaceutical Executive Editors
What does it take to keep your employees on board? In the 1980s, employees looked for performance pay. In the 1990s, they wanted job security. Employees' needs have changed as society has, yet one thing has remained the same: Employees are always looking for something more out of their jobs. They want better quality of life at work.
Dec 01, 2005
Pharmaceutical Executive
In an article for the New York Times, reporter Damien Cave pointed out how few heroes have been publicly recognized by the Administration in the current war. Despite the fact that there have been incredible acts of heroism and gutsy leadership on the ground of this Iraq war, the powers that be, for the most part, are calling no attention to it—at least no prime-time attention. Damien's most damning example came from Major Bruce Norton, a military historian and author of Encyclopedia of American Military Heroes, who recounted how a Marine recently received his Navy Cross, the second-highest military honor—not with ceremony and honor, but in the mail.
Nov 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Valeant is banking on Viramidine, a pro-drug of its longtime cash cow, ribavirin, to catapult the company to the next level.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way.
Oct 01, 2005
Pharmaceutical Executive
Market researchers often fail to realize that whenever they collect competitor information they are in fact collecting competitive intelligence. The same is true in reverse.
native1_300x100
lorem ipsum